HER2阳性乳腺肿瘤≤10mm但未侵犯淋巴结（T1abN0）的患者进行辅助用曲妥珠单抗治疗的益处还没有得到充分研究。本系统综述和荟萃分析的目的是检查辅助用曲妥珠单抗是否能够提高这些患者的预后。通过对数据库的搜索，找到了评估曲妥珠单抗对乳腺癌特异生存率（BCSS）、无病生存时间（DFS）、远处无复发生存期（DRFS）、总生存时间（OS）或无复发生存时间（RFS）的干预性和观察性研究。共检索到了12项研究考察了曲妥珠单抗的效果，以及9项对照研究未采用曲妥珠单抗（n=6,927）。中位随访时间为36-123个月。通过四项和两项研究发现，接受曲妥珠单抗和化疗的患者的DFS（风险比（HR）0.14，P＜0.0001）和OS（HR 0.17，p=0.011）明显提高，相对比起未采用曲妥珠单抗/化疗。即使未使用曲妥珠单抗治疗，患者的预后也很好：5年DFS为88.3%，5年总生存率为95.9%。版权所有 © 2023 Elsevier B.V.出版。

The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors ≤10mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and meta-analysis was to examine if adjuvant trastuzumab improves the prognosis in these patients. Databases were searched to identify interventional and observational studies evaluating the effect of trastuzumab on breast cancer specific survival (BCSS), disease free survival (DFS), distant recurrence free survival (DRFS), overall survival (OS) or recurrence free survival (RFS). Twelve studies examining the effect of trastuzumab and nine control studies without trastuzumab were identified (n = 6,927). Median follow-up was 36-123 months. Significantly improved DFS (Hazard Ratio (HR) 0.14, p<0.0001) and OS (HR 0.17, p=0.011) were found for patients receiving trastuzumab and chemotherapy compared to no trastuzumab/chemotherapy based on four and two studies. The prognosis was good even for patients without trastuzumab treatment: 5-year DFS 88.3% and 5-year OS 95.9%.Copyright © 2023. Published by Elsevier B.V.